Quality ofLife
The prognosis of ILDs depends very much on the cause and varies from good (in the case of EB and some parasitic ILDs) to dismal (in the case of certain neoplasia and IPF). As the understanding of the pathogenesis of ILDs improves, novel therapies may be developed, but currently the array of drugs available to clinicians is frustrat- ingly limited.
Notwithstanding this scenario, careful and systematic management of the clinical consequences of ILDs, such as managing PH and environmental modification can vastly improve the patient's quality of life.Krafft E, Heikkila HP, Jespers P, et al. Serum and bronchoalveolar lavage fluid endothelin-1 concentrations as diagnostic biomarkers of canine idiopathic pulmonary fibrosis. Journal of Veterinary Internal Medicine. 2011; 25: 990-996.
Mesquita L, Lam R, Lamb CR, McConnell JF. Computed tomographic findings in 15 dogs with eosinophilic bronchopneumopathy. Veterinary Radiology and Ultrasound. 2015; 56: 33-39.
Reinero C, Cohn L. 2007. Interstitial lung diseases. Veterinary Clinics of North America: Small Animal Practice. 2007; 37: 937-947.
Wung D. Treatment of canine pulmonary arterial hypertension: is tadalafil an appropriate alternative to sildenafil? International Journal of Pharmaceutical Compounding. 2013; 17: 24-27.